Stock Events

Stock Events

Larkberget AB 

SEK2.09
0
-SEK0.03-1.42% Thursday 10:29

Statistics

Day High
2.18
Day Low
2.08
52W High
2.87
52W Low
1.98
Volume
214
Avg. Volume
57,547
Mkt Cap
41.38M
P/E Ratio
-
Dividend Yield
9.57%
Dividend
0.2

Upcoming

15
JUN
Dividend Ex
Estimated
 
19
JUN
Dividend Payment
Estimated
 
14
JUN 27
Dividend Ex
Estimated
 
18
JUN 27
Dividend Payment
Estimated
 

Dividends

9.57%Dividend Yield
Jun 25
SEK0.2
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

13FebExpected
Q4 0
Q4 2024
Q2 2025
Q4 2025
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-13,766.26%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
652,000Revenue
-89.76MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LARK.ST. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics develops RNA-targeted and gene therapies, competing in the neuromuscular and CNS sectors like CombiGene.
uniQure N.V.
QURE
Mkt Cap4.17B
uniQure is involved in developing gene therapies for patients with severe genetic diseases, aligning closely with CombiGene's mission.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics works on CRISPR/Cas9 gene editing, a technology that could be used in similar applications as CombiGene's gene therapy platform.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing sector, potentially targeting the same genetic disorders as CombiGene.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, which focuses on RNAi therapeutics, shares a similar approach to treating genetic diseases as CombiGene.
Voyager Therapeutics
VYGR
Mkt Cap259.04M
Voyager Therapeutics specializes in gene therapy targeting severe neurological diseases, directly competing with CombiGene's focus areas.

About

Lärkberget AB (publ) operates as an investment company. It is involved in Direct investments in low-risk instruments; Financial investments; Direct investments in unlisted profitable companies; and Reverse acquisition platform. The company was formerly known as CombiGene AB (publ) and changed its name to Lärkberget AB (publ) in June 2025. Lärkberget AB (publ) was incorporated in 1990 and is based in Östermalm, Sweden.
Show more...
CEO
Mr. Peter Ekolind
Employees
1
Country
SE
ISIN
SE0016101935

Listings

ST
SE
LARK.ST
F
DE
COJ0.F

0 Comments

Share your thoughts

FAQ

What is Larkberget AB stock price today?▼
The current price of LARK.ST is SEK2.09 SEK — it has decreased by -1.42% in the past 24 hours. Watch Larkberget AB stock price performance more closely on the chart.
What is Larkberget AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Larkberget AB stocks are traded under the ticker LARK.ST.
What is Larkberget AB market cap?▼
Today Larkberget AB has the market capitalization of 41.38M
What is Larkberget AB revenue for the last year?▼
Larkberget AB revenue for the last year amounts to 652,000 SEK.
What is Larkberget AB net income for the last year?▼
LARK.ST net income for the last year is -89.76M SEK.
Does Larkberget AB pay dividends?▼
Yes, LARK.ST dividends are paid annual. The last dividend per share was 0.2 SEK. As of today, Dividend Yield (FWD)% is 9.57%.
How many employees does Larkberget AB have?▼
As of April 05, 2026, the company has 1 employees.
When did Larkberget AB complete a stock split?▼
The last stock split for Larkberget AB was on June 07, 2021 with a ratio of 1:20.
Where is Larkberget AB headquartered?▼
Larkberget AB is headquartered in Östermalm, SE.